Biohaven Ltd. remains a clinical-stage biotech with no commercial product revenue, focusing on advancing multiple neurological and immunology candidates through expensive, multi-phase trials. As of Q2 2026, the company holds over $238 million in cash and maintains a healthy current ratio, supporting ongoing operations without near-term revenue. Its capital structure includes senior secured notes linked to future net sales of its lead candidate troriluzole, creating contingent obligations dependent on regulatory approval and commercialization success. The effectiveness of Biohaven's strategy hinges on clinical progression, milestone achievements, and timely regulatory milestones amid typical sector risks.